国产吉西他滨联合顺铂治疗28例晚期非小细胞肺癌

Combination of domestic gemcitabine and cisplatin in treatment of 28 patients with advanced non-small cell lung cancer

目的：评价国产吉西他滨（gemcitabine,GEM）联合顺铂方案治疗晚期非小细胞肺癌的疗效和不良反应。方法：对经病理组织学或细胞学证实的28例晚期非小细胞肺癌患者采用GP方案化疗：GEM1000mg/m^2ivdrip第1、8日,DDP30mg/m^2ivdrip第1-3日,21日为1周期。结果：CR0例,PR12例,SD14例,PD2例,总有效率为42.8%,初治、复治各14例,均有6例PR,有效率均为42.8%,不良反应以消化道反应及白细胞、血小板下降为主,均可耐受。结论：国产吉西他滨联合顺铂对晚期非小细胞肺癌有较好疗效,毒副反应可以耐受,可作为一线或二线化疗方案。

Objective：To evaluate the effect and adverse effect of the combination of domestic gemcitabine and cisplatin in the treatment of 28 patients with advanced non-small cell lung cancer（NSCLC）.Methods： Twenty eight cases of pathologically comfirmed advanced NSCLC were treated with combined chemotherapy including gemcitabine（GEM） 1000mg/m^2 ivdrip day 1 and day 8,DDP30mg/m^2 ivdrip day 1 to day 3, a cycle was 21 days. Results： There was no CR, PR was 12 in 28 cases（42.80%）,SD was 14 cases, and PD 2 cases. An objective response was obtained in 42.8%（RR 12/28） of patients（12PR）,the response rate was 42.8% in proviously untreated patients and in prevoiously treated patients , the main adverse effects were gastrointestinal reation and leakopenia and thrombocytopenia. Conclusion： Domestic gemcitabine combined with cisplatin was effective in treatment of patients with advanced non-small cell lung cancer, the patients tolerated the therapy well, so this therapy is hoped to be the first-line or the second-line scheme for advanced NSCLC patients.